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Abstract 
 
Background: Approximately 50% of Epidermal growth factor receptor (EGFR) 
mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine 
kinase inhibitors (TKIs) will acquire resistance by the T790M mutation. 
Osimertinib is the standard of care in this situation. The present study assesses 
the efficacy of osimertinib when T790M status is determined in circulating cell-
free tumour DNA (ctDNA) from blood samples in progressing advanced EGFR-
mutant NSCLC patients. 
Material and methods: ctDNA T790M mutational status was assessed by 
Inivata InVisionTM (eTAm-SeqTM) assay in 48 EGFR-mutant advanced NSCLC 
patients with acquired resistance to EGFR TKIs without a tissue biopsy between 
April 2015 and April 2016. Progressing T790M-positive NSCLC patients 
received osimertinib (80 mg daily). The objectives were to assess the response 
rate to osimertinib according to Response Evaluation Criteria in Solid Tumours 
(RECIST) 1.1, the progression-free survival (PFS) on osimertinib, and the 
percentage of T790M positive in ctDNA. 
Results: The ctDNA T790M mutation was detected in 50% of NSCLC patients. 
Among evaluable patients osimertinib gave a partial response rate of 62.5% 
and a stable disease rate of 37.5%. All responses were confirmed responses. 
After median follow up of 8 months, median PFS by RECIST criteria was not 
achieved (95% CI: 4-NA), with 6- and 12-months PFS of 66.7% and 52%, 
respectively.  
Conclusions: ctDNA from liquid biopsy can be used as a surrogate marker for 
T790M in tumour tissue.  
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Key message: Liquid biopsies are a usufull tool for personalising treatment in 
lung cancer patients. Detection of T790M at low levels in plasma samples of 
EGFR-mutant NSCLC patients predicts efficacy to osimertinib. 
 
 
  
Introduction: 
 
The activated epidermal growth factor receptor (EGFR) mutation is present in 
almost 50% of patients with advanced non-small cell lung cancer (NSCLC) who 
are of Asian ethnicity compared with only 12% in the Caucasian population [1]. 
These mutations predict sensitivity to first- and second-generation EGFR 
tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib or afatinib. Response 
rate and progression-free survival with EGFR TKIs are superior to standard 
first-line platinum doublet chemotherapy, making them the standard of care [2]. 
However, tumours invariably develop acquired resistance 9 to 13 months after 
treatment initiation. The substitution of threonine to methionine at amino acid 
position 790 (T790M) in exon 20 of the EGFR gene reduces first-generation 
EGFR TKIs binding, and accounts for over half of acquired resistance 
mechanisms [3, 4]. 
Knowledge of acquired resistance mechanisms to EGFR TKIs was one of the 
triggers behind the development of personalised therapies, with the introduction 
of the third-generation EGFR-TKIs, which are active against sensitive, as well 
as resistant T790M EGFR mutations, such as osimertinib [5]. Both the FDA and 
the EMA recently approved osimertinib in patients with acquired EGFR T790M 
mutations tested in a tumour-tissue biopsy or in plasma [6, 7], but noted that 
osimertinib efficacy has not been prospectively established in patients where 
T790M mutation was determined in plasma with unknown status in the tissue. 
Lack of available tissue for performing molecular profile (such as when bone 
metastases are present, as reported in almost 50% of cases [8], requiring 
decalcification of the samples impairing DNA quality), the location or size of the 
tumour at progression, and the risk of complications, are serious limitations to 
re-biopsy NSCLC tumours. Moreover, single site biopsies may not provide a 
representative profile of the overall predominant resistance mechanisms for a 
given patient [9].  
Liquid biopsies based on circulating cell-free tumour DNA (ctDNA) analysis 
have been described as surrogate samples for molecular analysis replacing 
solid tumours [10], and may allow real-time sampling of multifocal clonal 
evolution [11]. Here we assessed the feasibility of identifying T790M mutations 
in ctDNA isolated from blood samples in a cohort of EGFR-mutant NSCLC 
patients with progression under first- or second-generation EGFR TKIs without 
a tissue biopsy at progression, in order to detect acquired resistance. The 
efficacy of osimertinib in the ctDNA T790M-positive NSCLC patients was also 
assessed.  
 
Patients and methods 
 
Patients  
Eligible patients treated at the Gustave Roussy (Villejuif, France) between April 
2015 and April 2016 were included in this study. Patients had to have advanced 
NSCLC, the presence of a common activating EGFR-mutation in the initial 
biopsy (Del19, L858R), clinical or radiological progression to at least one first- 
or second-generation EGFR TKI [12], and ineligibility for a new tissue biopsy 
(due to lack of available tissue, localisation and/or patient’s refusal) for testing 
T790M status at the time of progression. There was no upper limit for the 
number of prior EGFR-inhibitor or systemic therapies. All patients provided 
written informed consent for biomedical research (CEC-CTC IDRcb2008-
AOO585-50) and the institutional ethics committee approved the protocol. 
Osimertinib at 80 mg daily was prescribed as a part of the French Expanded 
Access Program in France, which allow its prescription when T790M was 
present in tumour-tissue biopsy or in a liquid biopsy.  
 
Outcomes  
The primary endpoint was to determine the overall response rate with 
osimertinib in patients treated on the basis of a positive T790M mutational 
status from a liquid biopsy results. Secondary endpoints included: the 
percentage of T790M mutation-positive patients identified by ctDNA analysis 
from pretreated EGFR-mutant patients with progression to systemic treatment, 
progression free survival by radiological criteria and investigator’s criteria and 
overall survival on osimertinib. 
As an exploratory objective, correlation between RECIST radiological 
responses with osimertinib and three ctDNA predictors was evaluated: (A) 
T790M allele fraction, (B) EGFR activating mutation allele fraction, and (C) ratio 
of T790M and EGFR activating mutation allele fraction. 
Progression free survival (PFS) was calculated from the initiation of osimertinib 
treatment until the date of progression by RECIST 1.1 or death (whichever 
came first), with censoring at the date of last follow-up if the patient had not 
progressed. PFS by investigator (time to off-osimertinib progression if 
osimertinib therapy was extended beyond progression at investigator discretion) 
was also assessed. Overall survival (OS) was calculated from the initiation of 
osimertinib treatment until the date of death. 
 
InVision™ (eTAm-Seq™) analysis 
10 ml of blood were collected in K2-EDTA tubes and processed at the time of 
disease progression (clinical or radiological). DNA was extracted from < 5 ml of 
plasma and analysed by the InVision assay, using enhanced Tagged Amplicon-
Sequencing; eTAmSeq™, [13] which was developed from TAm-Seq® assay 
[14] (Supplement; Appendix 1).  
 
Radiologic assessments 
Prior to prescribing osimertinib, all patients underwent tumour imaging, 
including computed tomography of the chest and abdomen and/or PET-scan. 
Brain imaging was performed in cases of symptoms. Restaging scans were 
obtained at least 4-weeks after treatment initiation and then every 6 to 8 weeks. 
Senior radiologist (C.C.) centrally reviewed the response rate and determined 
best response to osimertinib according to RECIST v1.1 [15]. The objective 
response rate was defined as the percentage of patients with response 
(complete or partial) at first restaging after osimertinib initiation. Confirmed 
responses were defined as persistent responses (partial or complete) at second 
radiological assessment. Only evaluable patients who received osimertinib 
based on positivity for the T790M mutation from ctDNA liquid biopsies were 
evaluated for the response rate.  
 
Results 
 
Patient characteristics  
Forty-eight advanced EGFR-mutant NSCLC patients with radiological or clinical 
progression on systemic treatment were evaluated for T790M status in a liquid 
biopsy. Median age was 65 years (range 37-83); 36 (75%) patients were 
women and 58% were never-smoker. EGFR mutation status was Del19 in 33 
(69%) and L858R in 15 (31%) NSCLC patients.  
 
T790M status in a liquid biopsy 
The T790M positivity in ctDNA was reported in 24 out of 48 (50%) NSCLC 
patients. (Figure S1)  
Activating EGFR mutational status in ctDNA analysis confirmed that the original 
mutation was maintained in 23 out of 24 T790M-positive samples. The T790M 
mutation positivity was more frequent among patients with the EGFR Del19 
mutation (20 out of 33 patients, 61%) compared to the EGFR L858R mutation 
(4 out of 15, 27%). Concomitant mutations to T790M mutation were reported in 
three patients (Table 1).  
For 9 of the 24 patients with ctDNA T790M-positivity, the T790M allele fraction 
(AF) was lower than 0.5% in the liquid biopsy (Table S1). 
 
Osimertinib response rate  
Of the 24 NSCLC patients with a T790M mutation in the ctDNA, 18 received 
osimertinib at progression and were evaluated for response (Figure S1). 
Table 1 summarizes baseline demographic characteristics of NSCLC patients 
who were T790M positive by ctDNA and treated with osimertinib. Median age 
was 63 years, and a total of 78% of patients (14 of 18) were female. All the 
patients had received at least one prior EGFR TKI. Three or more previous 
systemic treatment lines were reported in up to 65% of patients and in 70% of 
cases an EGFR TKI was the last treatment before starting osimertinib.  
Two patients were not evaluated for response: one having only bone 
metastases and the other died due to a treatment-unrelated cerebral 
haemorrhage. Of the 16 evaluable patients, 10 had a partial response (62.5%), 
and 6 had stable disease (37.5%). No patients had complete response or 
disease progression as best response (Table 1 and Figure 1).  
Among those patients with partial response (n=10), all had second radiological 
assessment to confirm response, and the response was confirmed in 90% of 
patients (1 patient progressed at the second radiological assessment). Of note, 
one patient previously treated with rociletinib, received osimertinib as tenth line 
treatment achieving a partial response.  
The median time between the blood draw in which ctDNA T790M positivity was 
detected and start of osimertinib treatment was 6 weeks. 
 
Correlation between RECIST and ctDNA predictors 
Correlations between RECIST radiological responses with osimertinib and three 
ctDNA predictors: (A) T790M allele fraction, (B) EGFR activating mutation allele 
fraction, and (C) ratio of T790M and EGFR activating mutation allele fraction 
were evaluated, however, none showed significance (Figure 2), but a trend (p-
value 0.09-0.15) was observed for larger decrease in tumour size for smaller 
mutant allele fractions of T790M or EGFR activating mutations. Of the seven 
cases with best response (decrease of 50% or more in size), 3 cases had 
T790M detected at <0.25%.  
 
Progression Free Survival and Overall Survival  
After a median follow up of 8.5 months, median PFS on osimertinib by RECIST 
1.1 criteria was not achieved (95% CI: 4-NA), with a 6- and 12-months PFS of 
66.7% and 52%, respectively (Figure 3). By investigator, median PFS was 13 
months (95% CI: 8-NA), with 6- and 12-months PFS of 79% and 70%, 
respectively (Figure S3). At the time of cut-off 4 patients had died; hence overall 
survival (OS) was not achieved. 1-year OS was 78% (95%CI: 59-97) (Figure 
S2). 
 
 
Discussion 
 
Osimertinib is a third-generation oral EGFR TKI developed to treat tumours 
bearing sensitizing EGFR and acquired resistant T790M-mutations, that spares 
the wild type form of the receptor [16]. To the best of our knowledge, our 
analysis is the first to prospectively test in a real-world setting the efficacy of 
osimertinib according to ctDNA results. In this study, osimertinib achieved a 
62.5% response rate and 12-months PFS of 52% among NSCLC patients who 
were T790M-mutation positive, based on ctDNA analysis by a multiplexed deep 
sequencing [13] assay. These results are comparable to the efficacy reported 
with osimertinib in patients with T790M mutation detected in a tumour tissue 
biopsy [5, 16]. In the phase 3 AURA3 study, osimertinib provided a 71% of 
response rate and 12-months PFS of 44% in pre-treated and tissue T790M-
mutation positive NSCLC patients [16]. However, in the phase I AURA trial, 
some patients with T790M-mutation negative also responded to osimertinib [5] 
reflecting the inadequacy of tissue-biopsy for catching tumour heterogeneity. In 
the post hoc exploratory analysis of the samples from the phase I AURA trial, 
which included 216 patients (73% were T790M-positive in the tumour) 
osimertinib gave a response rate of 63% among patients who were T790M-
mutation positive according to central blood-test genotyping by the BEAMing 
method (allelic fraction for positive results for T790M mutation ≥ 0.06%) [17]. 
Liquid biopsies based on ctDNA analysis are described as surrogate samples 
for tumour molecular analysis [10], and also as potential dynamic markers for 
monitoring the efficacy of EGFR TKI [18, 19] and early detection of resistance 
mutations [20]. Liquid biopsy assays have been developed for analysis of hot-
spot mutations and gene panels. Hot-spot assays can offer lower complexity 
and some PCR-based assays for detection of mutations in EGFR (including 
activating mutations and the T790M mutation) have received CE-mark [21] and 
approval by the FDA for in-vitro use [22]. Several commercial laboratories now 
offer sensitive assays for ctDNA using targeted deep sequencing of gene 
panels that include EGFR. In our study, the rate of T790M mutation positivity in 
a liquid biopsy among EGFR-mutant patients progressing on systemic 
treatment was 50%, which is consistent with previous biopsy series [3, 4] and 
clinical trials [5, 23]. In a recent prospective exploratory analysis, the resistance-
associated mutation in ctDNA (tested by cobas EGFR Mutation Testv2) among 
EGFR-mutant NSCLC patients was detected in 50% of patients, and 
concordance with tumour biopsy-derived genotyping was 61% [24]. Among 
patients with sufficient material for concurrent ctDNA and tumour-derived 
genotyping, ctDNA identified the T790M mutation in 5 of 25 (20%) in whom the 
concurrent study biopsy was negative. Similarly, in the phase I AURA trial, 
T790M was detected in plasma of 30% of patients with T790M-negative 
tumours [17]. Discrepancies between tumour biopsy and ctDNA genotyping 
may result from technological differences, or sampling of different tumour cell 
populations in a heterogeneous setting [24]. Studies focusing on the 
discrepancy of T790M mutation between tissue and plasma samples are 
underway using amplification-refractory mutation system (ARMS) and droplet 
digital PCR methods (NCT02418234). Moreover, recent data suggest that 
ctDNA T790M mutation derived from NSCLC tumours can be detected with high 
sensitivity in urine as well as in plasma, enabling complementary modes of 
tissue and liquid biopsies in EGFR TKI resistant NSCLC [25].  Although 
sensitivity and specificity of ctDNA varies across different technology platforms 
[26], the establishment of robust and standardised protocols for blood sampling, 
processing, storage, DNA extraction and analysis will support liquid biopsies as 
new standard tests in the near future for tumour genotyping as well as 
predictive biomarkers [26].  
In this setting, the relatively low number of patients, the heavy degree of pre-
treatment population included in our analysis (median of four previous treatment 
lines, 33% with at least two EGFR TKIs before osimertinib initiation and two 
patients previously pre-treated with T790M-inhibitors), the lack of corresponding 
tumour sample for all patients, and the heterogeneity in terms of lines of 
treatment are all considered as potential limitations. Moreover, ctDNA cut-off 
points to define the clinical relevance of the findings specifically based on 
functional consequences, namely their ability to predict therapeutic 
responsiveness, are required before ctDNA can be routinely implemented in 
clinical practice. Interestingly, the observation in our cohort that the T790M 
allele fraction was not significantly correlated with clinical response suggests 
that any level of T790M positivity may be clinically relevant, independent of the 
allele fraction threshold. However, the relatively long time delay between 
establishment of ctDNA T790M positivity and osimertinib initiation may mean 
that the allele fraction at the moment of treatment initiation may be higher than 
the reported results.  Our data suggests a possible importance for detection of 
T790M at low allele fractions, but additional studies are needed to confirm the 
minimum biological threshold with clinical relevance.  
Testing tumour tissue is so far the recommended method for detecting the 
presence of the resistant T790M mutation among EGFR-mutant NSCLC 
patients and tailoring treatment [6, 7], Prior biopsy-based studies have reported 
multiple acquired resistance mechanisms in approximately 5% to 15% of 
NSCLC patients with EGFR TKIs [3, 4]. However, up to 23% of tumour tissue 
specimens available at the time of acquired resistance have been reported as 
providing limited, low quality material for tumour genotyping [4, 24], and may not 
be representative of the entire genomic landscape of the tumour [9, 27]. In 
addition, not all patients are suitable for new tissue biopsy at progression, which 
can thereby delay treatment initiation [28]. Recently, mechanisms of acquired 
resistance after first-line EGFR TKI were analysed in ctDNA by CAPP-Seq in 41 
EGFR-mutant NSCLC patients. At least 46% of these tumours had developed 
another mechanism of acquired resistance in addition to T790M mutation, and 
these multiple resistance mechanisms were associated with poorer outcome to 
third generation EGFR TKIs [29]. In our analysis, blood samples from three 
patients reported concomitant mutations with no clear correlation with outcome: 
one PIK3CA mutation, previously reported as mechanism of acquired 
resistance [3]; and two other mutations, STK11 and NRAS mutation, not 
previously described as acquired resistance mechanisms to first- or second-
generation EGFR TKI. However, NRAS mutation has been recently reported as 
an acquired mechanism of resistance to osimertinib in preclinical models [30].  
ctDNA analysis may allow the development of rational trials for personalised 
selection of combined therapies to address intratumoural heterogeneity, 
however, a risk-benefit assessment should be performed to avoid substantial 
increases in toxicity. 
 
Conclusion: 
 
In this analysis of liquid biopsies in a small cohort of EGFR-mutant NSCLC 
patients with acquired resistance to systemic treatment, our results provide 
relevant clinical data about the efficacy of osimertinib in a real-world setting 
among patients whereT790M-positivity was detected in ctDNA, supporting the 
use of such liquid biopsies for personalising treatment in lung cancer patients. 
Our results suggest a possible clinical importance for detection of T790M at low 
levels in plasma samples.  
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 Patient Gender 
Age 
(years) 
Pack-
yrs 
EGFR 
mutation 
T790M 
AF (%) 
Previous 
systemic 
treatments 
Previous 
EGFR TKI 
Other mutations (#) 
Last treatment 
before 
Osimertinib 
RECIST 
Osimertinib 
1 M 51 0 Del19 0.41 3 1 TP53 (P151X, R273H) Erlotinib NE 
2 F 56 0 Del19 15.96 3 2 TP53 (Q331*, V225A) Erlotinib SD (-10%) 
3 M 54 6 Del19 0.86 3 1 
TP53 (R337C) 
STK11 (P179L) 
Erlotinib -BVZ PR (-50%) 
4 F 37 0 Del19 1.06 3 2 TP53 (Q165*) Erlotinib PR (-84%) 
5 M 67 6 Del19 1.60 4 2 CTNBB1 (S37S) Pem / Cis PR (-50%) 
6 F 83 10 Del19 6.96 2 2 CTNNB1 (S33C) Erlotinib SD (0%) 
7 F 67 0 Del19 19.60 1 1 
CDKN2A (frameshift) 
TP53 (frameshift) 
Erlotinib PR (-50%) 
8 F 70 0 L858R 0.25 2 1 NRAS (A59G) Pem SD (-26%) 
9 F 66 5 L858R 0.07 10 3 
+
 - Erlotinib PR (-65%) 
10 F 81 0 L858R 5.38 4 3 
TP53 (P60X, splice) 
PIK3CA (E545K) 
Pem PR (-33%) 
11 F 70 0 Del19 0.31 3 1 TP53 (R282W) Pem NE 
12 F 58 0 Del19 0.24 6 2 - Erlotinib PR (-68%) 
13 F 54 0 Del19 2.24 3 2 - Pem / Cb SD (9%) 
14 F 59 10 Del19 0.14 2 1 TP53 (I232S) Gefitinib PR (-50%) 
15 F 67 2 L858R 0.30 3 1 EGFR (K860I) Erlotinib SD (-20%) 
16 M 61 20 Del19 0.70 5 3 
++
 TP53 (E343*, C238Y, C135X) Afatinib SD (-18%) 
17 F 54 3 Del19 3.95 2 1 TP53 (R249S) Gefitinib PR (-32%) 
18 F 65 0 Del19 0.68 1 1 CTNNB1 (S37C) Gefitinib PR (-32%) 
M: Male. F: Female. AF: Allelic Fraction. BVZ: Bevacizumab. Pem / Cis: Pemetrexed / Cisplatin. Pem / Cb: Pemetrexed / Carboplatin.  
NE: Not evaluable. SD: Stable disease. PR: Partial Response 
# other mutation at the moment of T790M positive in the  liquid biopsy (all patients had the common EGFR mutation at the time of T790M mutation positive, 
except patient number 15 whom original EGFR Del19 mutation was not found at acquired resistance). 
+
This patient had already received rociletinib. 
++
This patient has already been treated with osimertinib.  
 
Table 1. Patients’ characteristics with T790M mutation positive in a liquid biopsy who received osimertinib 
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Appendix 1. Supplement.  
The InVision assay, sequences regions in 35 genes including a panel of 
“hotspot” regions of interest and full gene coverage of selected genes. 
Sequences were generated using Illumina sequencing and molecular analysis, 
including status for T790M mutation assessed based on Inivata’s validated 
ISoMA analytical pipeline. In this study, samples were analysed using a 
combination of Inivata core gene panels version 1.2 for the first 15 patients and 
version 1.4 for the remaining 33 patients [16]. 
 
Figure S1. Flowchart presenting T790M status and osimertinib treatment.  PD: 
progressive disease. CT: chemotherapy 
 
 
 
 
 
 
 
Figure S2. Progression Free Survival (PFS) by investigator. NA: not achieved  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. Overall survival (OS) on osimertinib. NA: not achieved  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S1. Allele fraction of EGFR activating mutation and T790M mutation 
positive.  
 
 
Patient Gender 
Age 
(years) 
EGFR 
Mutation subtype 
AF of 
T790M (%) 
AF of EGFR mutation (%) 
1 M 51 Del19 0.41 0.93 
2 F 56 Del19 15.96 38.46 
3 M 54 Del19 0.86 12.45 
4 F 37 Del19 1.06 2.48 
5 M 67 Del19 1.60 5.93 
6 F 83 Del19 6.96 10.84 
7 F 67 Del19 19.60 51.61 
8 F 70 L858R 0.25 1.15 
9 F 66 L858R 0.07 0.03 
10 F 81 L858R 5.38 18.8 
11 F 70 Del19 0.31 1.51 
12 F 58 Del19 0.24 0.75 
13 F 54 Del19 2.24 29.76 
14 F 59 Del19 0.14 0.25 
15 F 67 L858R 0.30 0.11 
16 M 61 Del19 0.70 31.73 
17 F 54 Del19 3.95 7.25 
18 F 65 Del19 0.68 3.50 
19 M 67 Del19 4.60 25.25 
20 F 70 Del19 7.54 37.39 
21 M 54 Del19 0.10 18.05 
22* M 55 Del19 4.02 25.01 
23 F 48 Del19 0.11 0.31 
24* F 67 Del19 0.59 2.36 
M: Male. F: Female. AF: Allelic Fraction.  *: Patients with C797S mutation (both currently treated 
with osimertinib) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
